In part 4 of this Exclusive Interview, Joel Goldsmith talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the effectiveness of the new CGM system in the management of diabetes.

In part 5 of this Exclusive Interview, Joel Goldsmith talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about Abbott's response to the ambulatory glucose profile recommendation by AACE.

In part 6, the conclusion of this Exclusive Interview, Joel Goldsmith talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the response of patients to the new CGM system.

It is not unusual for many of us to begin to take things about diabetes for granted and forget to share some information with our patients. After showing many people how to use an insulin pen, medical professionals often will forget little things like taking the cap off of the …

Female, 25 years of age related a story to me she recalls from years back. Patient was diagnosed with type 1 diabetes at 5 years of age. Mother has had type 1 diabetes since childhood, so patient had learned a lot about living with type 1 diabetes since a young child. Patient is and has been a very independent person. Both her mother and father trusted her and for the most part worked with her pediatrician to manage her diabetes.

In Part 4 of this Exclusive Interview, Dr. Osama Hamdy talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about how to safely fast to benefit weight loss and how to eat for maximum satiety.

In this week's Homerun Slides, a focus on empagliflozin, another therapeutic approach in the treatment of CKD in this albuminuria presentation by Dr. Claude Lardinois.

What is “metabolomics?” Metabolomics is an emerging field of analytical chemistry whose goal is to quantify all metabolites in a biologic sample, typically through application of multiple analytical platforms that enable determinations across a variety of metabolite classes. As with other omics-based technologies, this comprehensive coverage of metabolism has the benefit of allowing the observation of metabolic stressor effects not only at a single target, but also the ripple effect of the stressor, including compensatory responses, across the metabolic landscape.

This week insulin takes a front row in treating diabetes with the information on a new super rapid insulin. This insulin, discussed in this week’s item 2,  gives flexibility at meal time that has been lacking for a lot of patients. Also, as Animas leaves the insulin pump market, a …

Patients with type 2 diabetes not responding to basal insulin therapy alone may see glycemic improvement with a GLP-1 receptor agonist.